Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the moment, Eli Lilly.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
The Food and Drug Administration declared an end to the scarcity of Eli Lilly’s highly in-demand weight-loss and diabetes drugs on Thursday.
In the obesity drug industry, two players have really been throwing their weight around. There isn’t a third in sight.
Novo Nordisk’s share price fell over 8% on Wednesday after the company reported lower-than-expected sales of Wegovy.
Rest assured, competitors Deloitte, Ernst & Young, and PricewaterhouseCoopers are likely to follow in KPMG’s tracks.
For the crypto industry, President Trump is something of an enigma. But the launch of the Trump family coins was a bit, well, embarrassing.
President Donald Trump used the first hours of his second term in office Monday to make the emergency declaration.